Communiqués Humacyte, Inc.

Actions

HUMA

US44486Q1031

Marché Fermé - Nasdaq Autres places de cotation 19:00:00 03/07/2024			Varia. 5j.	Varia. 1 janv.
5,67 ^USD	+10,96 %		+13,40 %	+99,65 %

01/07	Le traitement ATEV de Humacyte reçoit une nouvelle désignation de la FDA ; les actions montent avant la cloche	MT
25/06	Humacyte, Inc. présente des données précliniques positives pour son programme de pancréas biovasculaire (Bvp ??)	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Humacyte Acellular Tissue Engineered Vessel Receives FDA's Regenerative Medicine Advanced Therapy Designation for Patients with Advanced Peripheral Artery Disease	02/07	AQ
Humacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)	01/07	AQ
Humacyte Presents Positive Preclinical Data for Its BioVascular Pancreas Program	26/06	AQ
Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program	25/06	AQ
Centers for Medicare and Medicaid Services Issues ICD-10-PCS Codes for Humacyte s Human Acellular Vessel	18/06	AQ
Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™)	17/06	AQ
Humacyte to Present at the Jefferies Global Healthcare Conference	30/05	AQ
Humacyte First Quarter 2024 Financial Results and Business Update	13/05	AQ
Humacyte to Participate at Upcoming Investor Conferences in May	13/05	AQ
Humacyte First Quarter 2024 Financial Results and Business Update	10/05	AQ
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024	06/05	AQ
Humacyte to Host Virtual KOL Event Hemodialysis Access, a Crossroads of Care, on March 28, 2024	27/03	AQ
Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024	26/03	AQ
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update	25/03	AQ
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update	22/03	AQ
Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024	18/03	AQ
Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference	04/03	AQ
Humacyte Announces Proposed Public Offering of Common Stock	01/03	AQ
Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference	01/03	AQ
Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock	01/03	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Humacyte, Inc.

Actions

HUMA

US44486Q1031

Communiqués

Filtres